Christalla Pithara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christalla Pithara has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Hannah B. Edwards
University of Bristol
5 shared publications - Sabi Redwood
The National Institute for Health and Care Research Applied Research Collaboration West (NIHR ARC West) at University Hospitals Bristol and Weston NHS Foundation Trust
5 shared publications - Barnaby C. Reeves
Bristol Medical School, University of Bristol, Bristol, UK
4 shared publications - Jenny L. Donovan
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
4 shared publications - Maria Pufulete
Bristol Medical School, University of Bristol, Bristol, UK
4 shared publications Sabi Redwood
The National Institute for Health and Care Research Applied Research Collaboration West (NIHR ARC West) at University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
4 shared publications
Latest Publications
- Open Access
- 16 July 2025
- Published by Springer Nature in Implementation Science Communications
- Vol. 6 (1) , 1-13
Lessons from using the Normalisation Process Theory to understand adherence to guidance on MgSO4 in preterm labour
Background: The administration of magnesium sulphate (MgSO4) in preterm labour is an evidence-based intervention recommended by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to prevent neurological damage to the infant. However, uptake varies across UK maternity units. We used findings from three studies in England, Scotland and Wales investigating implementation of guidance on MgSO4 as neuroprotectant in preterm-labour to understand how knowledge mobilisation can drive scaling and spread of improvement. Methods: Remote semi-structured interviews were carried out as part of an evaluation of (1) the PReCePT (Preventing Cerebral Palsy in Pre-Term Labour) National Programme, and (2) the PReCePT cRCT study, and as part of a qualitative study investigating MgSO4 guidance implementation in Scotland and Wales. Normalisation Process Theory informed data collection and analysis. Data were analysed using the framework method. Results: Interviews with 86 strategic and clinical leads and implementers from the three nations suggested that despite evidence being necessary and important for policy decision-making and clinical buy-in, improvement interventions were motivated by audit data and benchmarking. Scaling of improvement was driven by knowledge sharing, diffusion of innovation, and capacity building through relational structures (e.g. networks, communities) spanning the perinatal ecosystem. Local champions operating in multiple communities and networks as boundary-spanners connected national and regional leadership, patient group representatives, implementers i.e. clinical leads and champions, and perinatal clinical teams to enable knowledge mobilisation. Their work relied on backfill funding and protected time, and social-cognitive and social-structural resources in their settings. Sense-making, cognitive participation, collective action and reflexive monitoring work took place iteratively and dynamically within and across these structures on each level of the system. Conclusions: QI interventions driven by knowledge mobilisation can drive scaling and spreading of improvement, but require knowledge sharing and an infrastructure within the system to support improvement capacity building. Strong leadership with the ability to address power imbalances between co-actors, and secure protected funding for local champions is also required.
- 16 July 2025
- Published by Springer Nature in Implementation Science Communications
- Vol. 6 (1) , 1-13
Open AccessLessons from using the Normalisation Process Theory to understand adherence to guidance on MgSO4 in preterm labour
Background: The administration of magnesium sulphate (MgSO4) in preterm labour is an evidence-based intervention recommended by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to prevent neurological damage to the infant. However, uptake varies across UK maternity units. We used findings from three studies in England, Scotland and Wales investigating implementation of guidance on MgSO4 as neuroprotectant in preterm-labour to understand how knowledge mobilisation can drive scaling and spread of improvement. Methods: Remote semi-structured interviews were carried out as part of an evaluation of (1) the PReCePT (Preventing Cerebral Palsy in Pre-Term Labour) National Programme, and (2) the PReCePT cRCT study, and as part of a qualitative study investigating MgSO4 guidance implementation in Scotland and Wales. Normalisation Process Theory informed data collection and analysis. Data were analysed using the framework method. Results: Interviews with 86 strategic and clinical leads and implementers from the three nations suggested that despite evidence being necessary and important for policy decision-making and clinical buy-in, improvement interventions were motivated by audit data and benchmarking. Scaling of improvement was driven by knowledge sharing, diffusion of innovation, and capacity building through relational structures (e.g. networks, communities) spanning the perinatal ecosystem. Local champions operating in multiple communities and networks as boundary-spanners connected national and regional leadership, patient group representatives, implementers i.e. clinical leads and champions, and perinatal clinical teams to enable knowledge mobilisation. Their work relied on backfill funding and protected time, and social-cognitive and social-structural resources in their settings. Sense-making, cognitive participation, collective action and reflexive monitoring work took place iteratively and dynamically within and across these structures on each level of the system. Conclusions: QI interventions driven by knowledge mobilisation can drive scaling and spreading of improvement, but require knowledge sharing and an infrastructure within the system to support improvement capacity building. Strong leadership with the ability to address power imbalances between co-actors, and secure protected funding for local champions is also required.
- Open Access
- 18 October 2024
- Published by Springer Nature in Research Square
Knowledge mobilisation for translating evidence-based guidelines into practice. Lessons from using the Normalisation Process Theory to understand adherence to guidance on MgSO4 in preterm labour
Background The administration of magnesium sulphate (MgSO4) in preterm labour is an evidence-based intervention recommended by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to prevent neurological damage to the infant. However, uptake varies across UK maternity units. We used findings from implementation research in England, Scotland and Wales to explore knowledge mobilisation as a mechanism for improving adherence to clinical guidance. Methods Data were collected using semi-structured interviews for a process evaluation of the PReCePT (Preventing Cerebral Palsy in Pre-Term Labour) National Programme, the PReCePT cRCT study, and a study investigating MgSO4 guidance implementation in Scotland and Wales. Normalisation Process Theory informed data collection and analysis. Data were analysed using the framework method. Results Interviews with 68 strategic and clinical leads and implementers from the three nations suggested that despite evidence being necessary and important for policy decision-making, clinical leadership intervention decisions were motivated by audit data and benchmarking. Implementation success was impaired by degrees of silo working and rigid role boundaries, alongside differences in implementers’ ability to mobilise social-cognitive (e.g. commitment by maternity, neonatal and obstetric teams), and social-structural resources such as staff capacity, articulated workflows, and culture. Cross-organisational, diverse and collaborative communities of practice (CoPs) rooted in distributed leadership created a nexus between national and regional leadership, patient group representatives, implementers i.e. clinical leads and champions, and perinatal clinical teams. They provided a platform for CoP participants to build relationships and share knowledge, and together negotiate meaning, co-design implementation plans, share operational enablers such as strategies and products, and assess progress. Where training opportunities were provided alongside mentoring and peer support, CoPs created implementation resource i.e. capacity and capability within the perinatal system. Backfill funding for champions and protected time away from clinical duties were required to enable participation, especially for champions in resource-poor settings. Conclusions Opportunities to participate in collaborative, diverse, cross-organisational CoPs where knowledge and innovation can be co-created, shared, and spread across the perinatal ecosystem, can help address disparities in clinical teams’ ability to implement evidence-based interventions. Participation relies on backfill funding for champions, and a system-wide commitment to improvement.
- 18 October 2024
- Published by Springer Nature in Research Square
Open AccessKnowledge mobilisation for translating evidence-based guidelines into practice. Lessons from using the Normalisation Process Theory to understand adherence to guidance on MgSO4 in preterm labour
Background The administration of magnesium sulphate (MgSO4) in preterm labour is an evidence-based intervention recommended by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to prevent neurological damage to the infant. However, uptake varies across UK maternity units. We used findings from implementation research in England, Scotland and Wales to explore knowledge mobilisation as a mechanism for improving adherence to clinical guidance. Methods Data were collected using semi-structured interviews for a process evaluation of the PReCePT (Preventing Cerebral Palsy in Pre-Term Labour) National Programme, the PReCePT cRCT study, and a study investigating MgSO4 guidance implementation in Scotland and Wales. Normalisation Process Theory informed data collection and analysis. Data were analysed using the framework method. Results Interviews with 68 strategic and clinical leads and implementers from the three nations suggested that despite evidence being necessary and important for policy decision-making, clinical leadership intervention decisions were motivated by audit data and benchmarking. Implementation success was impaired by degrees of silo working and rigid role boundaries, alongside differences in implementers’ ability to mobilise social-cognitive (e.g. commitment by maternity, neonatal and obstetric teams), and social-structural resources such as staff capacity, articulated workflows, and culture. Cross-organisational, diverse and collaborative communities of practice (CoPs) rooted in distributed leadership created a nexus between national and regional leadership, patient group representatives, implementers i.e. clinical leads and champions, and perinatal clinical teams. They provided a platform for CoP participants to build relationships and share knowledge, and together negotiate meaning, co-design implementation plans, share operational enablers such as strategies and products, and assess progress. Where training opportunities were provided alongside mentoring and peer support, CoPs created implementation resource i.e. capacity and capability within the perinatal system. Backfill funding for champions and protected time away from clinical duties were required to enable participation, especially for champions in resource-poor settings. Conclusions Opportunities to participate in collaborative, diverse, cross-organisational CoPs where knowledge and innovation can be co-created, shared, and spread across the perinatal ecosystem, can help address disparities in clinical teams’ ability to implement evidence-based interventions. Participation relies on backfill funding for champions, and a system-wide commitment to improvement.
- Open Access
- 19 September 2024
- Published by Springer Nature in Research Square
Knowledge mobilisation for translating evidence-based guidelines into practice. Lessons from using the Normalisation Process Theory to understand adherence to guidance on MgSO4 in preterm labou
Background The administration of magnesium sulphate (MgSO4) in preterm labour is an evidence-based intervention recommended by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to prevent neurological damage to the infant. However, uptake varies across UK maternity units. We used findings from implementation research in England, Scotland and Wales to explore knowledge mobilisation as a mechanism for improving adherence to clinical guidance. Methods Data were collected using semi-structured interviews for a process evaluation of the PReCePT (Preventing Cerebral Palsy in Pre-Term Labour) National Programme, the PReCePT cRCT study, and a study investigating MgSO4 guidance implementation in Scotland and Wales. Normalisation Process Theory informed data collection and analysis. Data were analysed using the framework method. Results Interviews with 68 strategic and clinical leads and implementers from the three nations suggested that despite evidence being necessary and important for policy decision-making, clinical leadership intervention decisions were motivated by audit data and benchmarking. Implementation success was impaired by degrees of silo working and rigid role boundaries, alongside differences in implementers’ ability to mobilise social-cognitive (e.g. commitment by maternity, neonatal and obstetric teams), and social-structural resources such as staff capacity, articulated workflows, and culture. Cross-organisational, diverse and collaborative communities of practice (CoPs) rooted in distributed leadership created a nexus between national and regional leadership, patient group representatives, implementers i.e. clinical leads and champions, and perinatal clinical teams. They provided a platform for CoP participants to build relationships and share knowledge, and together negotiate meaning, co-design implementation plans, share operational enablers such as strategies and products, and assess progress. Where training opportunities were provided alongside mentoring and peer support, CoPs created implementation resource i.e. capacity and capability within the perinatal system. Backfill funding for champions and protected time away from clinical duties were required to enable participation, especially for champions in resource-poor settings. Conclusions Opportunities to participate in collaborative, diverse, cross-organisational CoPs where knowledge and innovation can be co-created, shared, and spread across the perinatal ecosystem, can help address disparities in clinical teams’ ability to implement evidence-based interventions. Participation relies on backfill funding for champions, and a system-wide commitment to improvement.
- 19 September 2024
- Published by Springer Nature in Research Square
Open AccessKnowledge mobilisation for translating evidence-based guidelines into practice. Lessons from using the Normalisation Process Theory to understand adherence to guidance on MgSO4 in preterm labou
Background The administration of magnesium sulphate (MgSO4) in preterm labour is an evidence-based intervention recommended by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to prevent neurological damage to the infant. However, uptake varies across UK maternity units. We used findings from implementation research in England, Scotland and Wales to explore knowledge mobilisation as a mechanism for improving adherence to clinical guidance. Methods Data were collected using semi-structured interviews for a process evaluation of the PReCePT (Preventing Cerebral Palsy in Pre-Term Labour) National Programme, the PReCePT cRCT study, and a study investigating MgSO4 guidance implementation in Scotland and Wales. Normalisation Process Theory informed data collection and analysis. Data were analysed using the framework method. Results Interviews with 68 strategic and clinical leads and implementers from the three nations suggested that despite evidence being necessary and important for policy decision-making, clinical leadership intervention decisions were motivated by audit data and benchmarking. Implementation success was impaired by degrees of silo working and rigid role boundaries, alongside differences in implementers’ ability to mobilise social-cognitive (e.g. commitment by maternity, neonatal and obstetric teams), and social-structural resources such as staff capacity, articulated workflows, and culture. Cross-organisational, diverse and collaborative communities of practice (CoPs) rooted in distributed leadership created a nexus between national and regional leadership, patient group representatives, implementers i.e. clinical leads and champions, and perinatal clinical teams. They provided a platform for CoP participants to build relationships and share knowledge, and together negotiate meaning, co-design implementation plans, share operational enablers such as strategies and products, and assess progress. Where training opportunities were provided alongside mentoring and peer support, CoPs created implementation resource i.e. capacity and capability within the perinatal system. Backfill funding for champions and protected time away from clinical duties were required to enable participation, especially for champions in resource-poor settings. Conclusions Opportunities to participate in collaborative, diverse, cross-organisational CoPs where knowledge and innovation can be co-created, shared, and spread across the perinatal ecosystem, can help address disparities in clinical teams’ ability to implement evidence-based interventions. Participation relies on backfill funding for champions, and a system-wide commitment to improvement.
- Open Access
- 10 September 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 131 (3) , 256-266
Quality improvement interventions to increase the uptake of magnesium sulphate in preterm deliveries for the prevention of cerebral palsy (PReCePT study): a cluster randomised controlled trial
Objective: To compare two quality improvement (QI) interventions to improve antenatal magnesium sulphate (MgSO4) uptake in preterm births for the prevention of cerebral palsy.Design: Unblinded cluster randomised controlled trial.Setting: Academic Health Sciences Network, England, 2018.Sample: Maternity units with ≥10 preterm deliveries annually and MgSO4 uptake of ≤70%; 40 (27 NPP, 13 enhanced support) were included (randomisation stratified by MgSO4 uptake).Methods: The National PReCePT Programme (NPP) gave maternity units QI materials (clinical guidance, training), regional support, and midwife backfill funding. Enhanced support units received this plus extra backfill funding and unit‐level QI coaching.Main outcome measures: MgSO4 uptake was compared using routine data and multivariable linear regression. Net monetary benefit was estimated, based on implementation costs, lifetime quality‐adjusted life‐years and societal costs. The implementation process was assessed through qualitative interviews.Results: MgSO4 uptake increased in all units, with no evidence of any difference between groups (0.84 percentage points lower uptake in the enhanced group, 95% CI −5.03 to 3.35). The probability of enhanced support being cost‐effective was 4 uptake in all maternity units. Enhanced support did not further improve uptake but may improve teamwork, and more accurately represented the time needed for implementation. Targeted enhanced support, sustainability of improvements and the possible indirect benefits of stronger teamwork associated with enhanced support should be explored further.
- 10 September 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 131 (3) , 256-266
Open AccessQuality improvement interventions to increase the uptake of magnesium sulphate in preterm deliveries for the prevention of cerebral palsy (PReCePT study): a cluster randomised controlled trial
Objective: To compare two quality improvement (QI) interventions to improve antenatal magnesium sulphate (MgSO4) uptake in preterm births for the prevention of cerebral palsy.Design: Unblinded cluster randomised controlled trial.Setting: Academic Health Sciences Network, England, 2018.Sample: Maternity units with ≥10 preterm deliveries annually and MgSO4 uptake of ≤70%; 40 (27 NPP, 13 enhanced support) were included (randomisation stratified by MgSO4 uptake).Methods: The National PReCePT Programme (NPP) gave maternity units QI materials (clinical guidance, training), regional support, and midwife backfill funding. Enhanced support units received this plus extra backfill funding and unit‐level QI coaching.Main outcome measures: MgSO4 uptake was compared using routine data and multivariable linear regression. Net monetary benefit was estimated, based on implementation costs, lifetime quality‐adjusted life‐years and societal costs. The implementation process was assessed through qualitative interviews.Results: MgSO4 uptake increased in all units, with no evidence of any difference between groups (0.84 percentage points lower uptake in the enhanced group, 95% CI −5.03 to 3.35). The probability of enhanced support being cost‐effective was 4 uptake in all maternity units. Enhanced support did not further improve uptake but may improve teamwork, and more accurately represented the time needed for implementation. Targeted enhanced support, sustainability of improvements and the possible indirect benefits of stronger teamwork associated with enhanced support should be explored further.
- Open Access
- 1 May 2023
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 27 (08) , 1-257
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies
Background: Bleeding among populations undergoing percutaneous coronary intervention or coronary artery bypass grafting and among conservatively managed patients with acute coronary syndrome exposed to different dual antiplatelet therapy and triple therapy (i.e. dual antiplatelet therapy plus an anticoagulant) has not been previously quantified. Objectives: The objectives were to estimate hazard ratios for bleeding for different antiplatelet and triple therapy regimens, estimate resources and the associated costs of treating bleeding events, and to extend existing economic models of the cost-effectiveness of dual antiplatelet therapy. Design: The study was designed as three retrospective population-based cohort studies emulating target randomised controlled trials. Setting: The study was set in primary and secondary care in England from 2010 to 2017. Participants: Participants were patients aged ≥ 18 years undergoing coronary artery bypass grafting or emergency percutaneous coronary intervention (for acute coronary syndrome), or conservatively managed patients with acute coronary syndrome. Data sources: Data were sourced from linked Clinical Practice Research Datalink and Hospital Episode Statistics. Interventions: Coronary artery bypass grafting and conservatively managed acute coronary syndrome: aspirin (reference) compared with aspirin and clopidogrel. Percutaneous coronary intervention: aspirin and clopidogrel (reference) compared with aspirin and prasugrel (ST elevation myocardial infarction only) or aspirin and ticagrelor. Main outcome measures: Primary outcome: any bleeding events up to 12 months after the index event. Secondary outcomes: major or minor bleeding, all-cause and cardiovascular mortality, mortality from bleeding, myocardial infarction, stroke, additional coronary intervention and major adverse cardiovascular events. Results: The incidence of any bleeding was 5% among coronary artery bypass graft patients, 10% among conservatively managed acute coronary syndrome patients and 9% among emergency percutaneous coronary intervention patients, compared with 18% among patients prescribed triple therapy. Among coronary artery bypass grafting and conservatively managed acute coronary syndrome patients, dual antiplatelet therapy, compared with aspirin, increased the hazards of any bleeding (coronary artery bypass grafting: hazard ratio 1.43, 95% confidence interval 1.21 to 1.69; conservatively-managed acute coronary syndrome: hazard ratio 1.72, 95% confidence interval 1.15 to 2.57) and major adverse cardiovascular events (coronary artery bypass grafting: hazard ratio 2.06, 95% confidence interval 1.23 to 3.46; conservatively-managed acute coronary syndrome: hazard ratio 1.57, 95% confidence interval 1.38 to 1.78). Among emergency percutaneous coronary intervention patients, dual antiplatelet therapy with ticagrelor, compared with dual antiplatelet therapy with clopidogrel, increased the hazard of any bleeding (hazard ratio 1.47, 95% confidence interval 1.19 to 1.82), but did not reduce the incidence of major adverse cardiovascular events (hazard ratio 1.06, 95% confidence interval 0.89 to 1.27). Among ST elevation myocardial infarction percutaneous coronary intervention patients, dual antiplatelet therapy with prasugrel, compared with dual antiplatelet therapy with clopidogrel, increased the hazard of any bleeding (hazard ratio 1.48, 95% confidence interval 1.02 to 2.12), but did not reduce the incidence of major adverse cardiovascular events (hazard ratio 1.10, 95% confidence interval 0.80 to 1.51). Health-care costs in the first year did not differ between dual antiplatelet therapy with clopidogrel and aspirin monotherapy among either coronary artery bypass grafting patients (mean difference £94, 95% confidence interval –£155 to £763) or conservatively managed acute coronary syndrome patients (mean difference £610, 95% confidence interval –£626 to £1516), but among emergency percutaneous coronary intervention patients were higher for those receiving dual antiplatelet therapy with ticagrelor than for those receiving dual antiplatelet therapy with clopidogrel, although for only patients on concurrent proton pump inhibitors (mean difference £1145, 95% confidence interval £269 to £2195). Conclusions: This study suggests that more potent dual antiplatelet therapy may increase the risk of bleeding without reducing the incidence of major adverse cardiovascular events. These results should be carefully considered by clinicians and decision-makers alongside randomised controlled trial evidence when making recommendations about dual antiplatelet therapy. Limitations: The estimates for bleeding and major adverse cardiovascular events may be biased from unmeasured confounding and the exclusion of an eligible subgroup of patients who could not be assigned an intervention. Because of these limitations, a formal cost-effectiveness analysis could not be conducted. Future work: Future work should explore the feasibility of using other UK data sets of routinely collected data, less susceptible to bias, to estimate the benefit and harm of antiplatelet interventions. Trial registration: This trial is registered as ISRCTN76607611. Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 27, No. 8. See the NIHR Journals Library website for further project information.
- 1 May 2023
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 27 (08) , 1-257
Open AccessBleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies
Background: Bleeding among populations undergoing percutaneous coronary intervention or coronary artery bypass grafting and among conservatively managed patients with acute coronary syndrome exposed to different dual antiplatelet therapy and triple therapy (i.e. dual antiplatelet therapy plus an anticoagulant) has not been previously quantified. Objectives: The objectives were to estimate hazard ratios for bleeding for different antiplatelet and triple therapy regimens, estimate resources and the associated costs of treating bleeding events, and to extend existing economic models of the cost-effectiveness of dual antiplatelet therapy. Design: The study was designed as three retrospective population-based cohort studies emulating target randomised controlled trials. Setting: The study was set in primary and secondary care in England from 2010 to 2017. Participants: Participants were patients aged ≥ 18 years undergoing coronary artery bypass grafting or emergency percutaneous coronary intervention (for acute coronary syndrome), or conservatively managed patients with acute coronary syndrome. Data sources: Data were sourced from linked Clinical Practice Research Datalink and Hospital Episode Statistics. Interventions: Coronary artery bypass grafting and conservatively managed acute coronary syndrome: aspirin (reference) compared with aspirin and clopidogrel. Percutaneous coronary intervention: aspirin and clopidogrel (reference) compared with aspirin and prasugrel (ST elevation myocardial infarction only) or aspirin and ticagrelor. Main outcome measures: Primary outcome: any bleeding events up to 12 months after the index event. Secondary outcomes: major or minor bleeding, all-cause and cardiovascular mortality, mortality from bleeding, myocardial infarction, stroke, additional coronary intervention and major adverse cardiovascular events. Results: The incidence of any bleeding was 5% among coronary artery bypass graft patients, 10% among conservatively managed acute coronary syndrome patients and 9% among emergency percutaneous coronary intervention patients, compared with 18% among patients prescribed triple therapy. Among coronary artery bypass grafting and conservatively managed acute coronary syndrome patients, dual antiplatelet therapy, compared with aspirin, increased the hazards of any bleeding (coronary artery bypass grafting: hazard ratio 1.43, 95% confidence interval 1.21 to 1.69; conservatively-managed acute coronary syndrome: hazard ratio 1.72, 95% confidence interval 1.15 to 2.57) and major adverse cardiovascular events (coronary artery bypass grafting: hazard ratio 2.06, 95% confidence interval 1.23 to 3.46; conservatively-managed acute coronary syndrome: hazard ratio 1.57, 95% confidence interval 1.38 to 1.78). Among emergency percutaneous coronary intervention patients, dual antiplatelet therapy with ticagrelor, compared with dual antiplatelet therapy with clopidogrel, increased the hazard of any bleeding (hazard ratio 1.47, 95% confidence interval 1.19 to 1.82), but did not reduce the incidence of major adverse cardiovascular events (hazard ratio 1.06, 95% confidence interval 0.89 to 1.27). Among ST elevation myocardial infarction percutaneous coronary intervention patients, dual antiplatelet therapy with prasugrel, compared with dual antiplatelet therapy with clopidogrel, increased the hazard of any bleeding (hazard ratio 1.48, 95% confidence interval 1.02 to 2.12), but did not reduce the incidence of major adverse cardiovascular events (hazard ratio 1.10, 95% confidence interval 0.80 to 1.51). Health-care costs in the first year did not differ between dual antiplatelet therapy with clopidogrel and aspirin monotherapy among either coronary artery bypass grafting patients (mean difference £94, 95% confidence interval –£155 to £763) or conservatively managed acute coronary syndrome patients (mean difference £610, 95% confidence interval –£626 to £1516), but among emergency percutaneous coronary intervention patients were higher for those receiving dual antiplatelet therapy with ticagrelor than for those receiving dual antiplatelet therapy with clopidogrel, although for only patients on concurrent proton pump inhibitors (mean difference £1145, 95% confidence interval £269 to £2195). Conclusions: This study suggests that more potent dual antiplatelet therapy may increase the risk of bleeding without reducing the incidence of major adverse cardiovascular events. These results should be carefully considered by clinicians and decision-makers alongside randomised controlled trial evidence when making recommendations about dual antiplatelet therapy. Limitations: The estimates for bleeding and major adverse cardiovascular events may be biased from unmeasured confounding and the exclusion of an eligible subgroup of patients who could not be assigned an intervention. Because of these limitations, a formal cost-effectiveness analysis could not be conducted. Future work: Future work should explore the feasibility of using other UK data sets of routinely collected data, less susceptible to bias, to estimate the benefit and harm of antiplatelet interventions. Trial registration: This trial is registered as ISRCTN76607611. Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 27, No. 8. See the NIHR Journals Library website for further project information.
- 1 October 2022
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- Vol. 10 (9) , 1-54
Developing decision support tools incorporating personalised predictions of likely visual benefit versus harm for cataract surgery: research programme
Background: Surgery for established cataract is highly cost-effective and uncontroversial, yet uncertainty remains for individuals about when to proceed and when to delay surgery during the earlier stages of cataract. Objective: We aimed to improve decision-making for cataract surgery through the development of evidence-based clinical tools that provide general information and personalised risk/benefit information. Design: We used a mixed methodology consisting of four work packages. Work package 1 involved the development and psychometric validation of a brief, patient self-reported measure of visual difficulty from cataract and its relief from surgery, named Cataract Patient-Reported Outcome Measure, five items (Cat-PROM5). Work package 2 involved the review and refinement of risk models for adverse surgical events (posterior capsule rupture and visual acuity loss related to cataract surgery). Work package 3 involved the development of prediction models for the Cat-PROM5-based self-reported outcomes from a cohort study of 1500 patients; assessment of the validity of preference-based health economic indices for cataract surgery and the calibration of these to Cat-PROM5; assessment of patients’ and health-care professionals’ views on risk–benefit presentation formats, the perceived usefulness of Cat-PROM5, the value of personalised risk–benefit information, high-value information items and shared decision-making; development of cataract decision aid frequently asked questions, incorporation of personalised estimates of risks and benefits; and development of a cataract decision quality measure to assess the quality of decision-making. Work package 4 involved a mixed-methods feasibility study for a fully powered randomised controlled trial of the use of the cataract decision aid and a qualitative study of discordant or mismatching perceptions of outcome between patients and health-care professionals. Setting: Four English NHS recruitment centres were involved: Bristol (lead centre), Brighton, Gloucestershire and Torbay. Multicentre NHS cataract surgery data were obtained from the National Ophthalmology Database. Participants: Work package 1 – participants (n = 822) were from all four centres. Work package 2 – electronic medical record data were taken from the National Ophthalmology Database (final set > 1M operations). Work package 3 – cohort study participants were from Bristol (n = 1200) and Gloucestershire (n = 300); qualitative and development work was undertaken with patients and health-care professionals from all four centres. Work package 4 – Bristol, Brighton and Torbay participated in the recruitment of patients (n = 42) for the feasibility trial and recruitment of health-care professionals for the qualitative elements. Interventions: For the feasibility trial, the intervention was the use of the cataract decision aid, incorporating frequently asked questions and personalised estimations of both adverse outcomes and self-reported benefit. Main outcome measures: There was a range of quantitative and qualitative outcome measures: questionnaire psychometric performance metrics, risk indicators of adverse surgical events and visual outcome, predictors of self-reported outcome following cataract surgery, patient and health-care practitioner views, health economic calibration measures and randomised controlled trial feasibility measures. Data sources: The data sources were patient self-reported questionnaire responses, study clinical data collection forms, recorded interviews with patients and health-care professionals, and anonymised National Ophthalmology Database data. Results: Work package 1 – Cat-PROM5 was developed and validated with excellent to good psychometric properties (Rasch reliability 0.9, intraclass correlation repeatability 0.9, unidimensionality with residual eigenvalues ≤ 1.5) and excellent responsiveness to surgical intervention (Cohen delta –1.45). Work package 2 – earlier risk models for posterior capsule rupture and visual acuity loss were broadly affirmed (C-statistic for posterior capsule rupture 0.64; visual acuity loss 0.71). Work package 3 – the Cat-PROM5-based self-reported outcome regression models were derived based on 1181 participants with complete data (R 2 ≈ 30% for each). Of the four preference-based health economic indices assessed, two demonstrated reasonable performance. Cat-PROM5 was successfully calibrated to health economic indices; adjusted limited dependent variable mixture models offered good to excellent fit (root-mean-square error 0.10–0.16). The personalised quantitative risk information was generally perceived as beneficial. A cataract decision aid and cataract decision quality measure were successfully developed based on the views of patients and health-care professionals. Work package 4 – data completeness was good for the feasibility study primary and secondary variables both before and after intervention/surgery (data completeness range 100–88%). Considering ability to recruit, the sample size required, instrumentation and availability of necessary health economic data, a fully powered randomised controlled trial (patients, n = 800, effect size 0.2 standard deviations, power 80%; p = 0.05) of the cataract decision aid would be feasible following psychometric refinement of the primary outcome (the cataract decision quality measure). The cataract decision aid was generally well-received by patients and health-care professionals, with cautions raised regarding perceived time and workload barriers. Discordant outcomes mostly related to patient dissatisfaction, with no clinical problem found. Limitations: The National Ophthalmology Database data are expected to include some errors (mitigated by large multicentre data aggregations). The feasibility randomised controlled trial primary outcome (the cataract decision quality measure) displayed psychometric imperfections requiring refinement. The clinical occurrence of discordant outcomes is uncommon and the study team experienced difficulty identifying patients in this situation. Future work: Future work could include regular review of the risk models for adverse outcomes to ensure currency, and the technical precision of complex-numbers analysis of refractive outcome to invite opportunities to improve post-operative spectacle-free vision. In addition, a fully powered randomised controlled trial of the cataract decision aid would be feasible, following psychometric refinement of the primary outcome (the cataract decision quality measure); this would clarify its potential role in routine service delivery. Conclusions: In this research programme, evidence-based clinical tools have been successfully developed to improve pre-operative decision-making in cataract surgery. These include a psychometrically robust, patient-reported outcome measure (Cat-PROM5); prediction models for patient self-reported outcomes using Cat-PROM5; prediction models for clinically adverse surgical events and adverse visual acuity outcomes; and a cataract decision aid with relevant general information and personalised risk/benefit predictions. In addition, the successful mapping of Cat-PROM5 to existing health economic indices was achieved and the performances of indices were assessed in patients undergoing cataract surgery. A future full-powered randomised controlled trial of the cataract decision aid would be feasible (patients, n = 800, effect size 0.2 standard deviations, power 80%; p = 0.05). Trial registration: This trial is registered as ISRCTN11309852. Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme and will be published in full in Programme Grants for Applied Research; Vol. 10, No. 9. See the NIHR Journals Library website for further project information.
- 1 October 2022
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- Vol. 10 (9) , 1-54
Developing decision support tools incorporating personalised predictions of likely visual benefit versus harm for cataract surgery: research programme
Background: Surgery for established cataract is highly cost-effective and uncontroversial, yet uncertainty remains for individuals about when to proceed and when to delay surgery during the earlier stages of cataract. Objective: We aimed to improve decision-making for cataract surgery through the development of evidence-based clinical tools that provide general information and personalised risk/benefit information. Design: We used a mixed methodology consisting of four work packages. Work package 1 involved the development and psychometric validation of a brief, patient self-reported measure of visual difficulty from cataract and its relief from surgery, named Cataract Patient-Reported Outcome Measure, five items (Cat-PROM5). Work package 2 involved the review and refinement of risk models for adverse surgical events (posterior capsule rupture and visual acuity loss related to cataract surgery). Work package 3 involved the development of prediction models for the Cat-PROM5-based self-reported outcomes from a cohort study of 1500 patients; assessment of the validity of preference-based health economic indices for cataract surgery and the calibration of these to Cat-PROM5; assessment of patients’ and health-care professionals’ views on risk–benefit presentation formats, the perceived usefulness of Cat-PROM5, the value of personalised risk–benefit information, high-value information items and shared decision-making; development of cataract decision aid frequently asked questions, incorporation of personalised estimates of risks and benefits; and development of a cataract decision quality measure to assess the quality of decision-making. Work package 4 involved a mixed-methods feasibility study for a fully powered randomised controlled trial of the use of the cataract decision aid and a qualitative study of discordant or mismatching perceptions of outcome between patients and health-care professionals. Setting: Four English NHS recruitment centres were involved: Bristol (lead centre), Brighton, Gloucestershire and Torbay. Multicentre NHS cataract surgery data were obtained from the National Ophthalmology Database. Participants: Work package 1 – participants (n = 822) were from all four centres. Work package 2 – electronic medical record data were taken from the National Ophthalmology Database (final set > 1M operations). Work package 3 – cohort study participants were from Bristol (n = 1200) and Gloucestershire (n = 300); qualitative and development work was undertaken with patients and health-care professionals from all four centres. Work package 4 – Bristol, Brighton and Torbay participated in the recruitment of patients (n = 42) for the feasibility trial and recruitment of health-care professionals for the qualitative elements. Interventions: For the feasibility trial, the intervention was the use of the cataract decision aid, incorporating frequently asked questions and personalised estimations of both adverse outcomes and self-reported benefit. Main outcome measures: There was a range of quantitative and qualitative outcome measures: questionnaire psychometric performance metrics, risk indicators of adverse surgical events and visual outcome, predictors of self-reported outcome following cataract surgery, patient and health-care practitioner views, health economic calibration measures and randomised controlled trial feasibility measures. Data sources: The data sources were patient self-reported questionnaire responses, study clinical data collection forms, recorded interviews with patients and health-care professionals, and anonymised National Ophthalmology Database data. Results: Work package 1 – Cat-PROM5 was developed and validated with excellent to good psychometric properties (Rasch reliability 0.9, intraclass correlation repeatability 0.9, unidimensionality with residual eigenvalues ≤ 1.5) and excellent responsiveness to surgical intervention (Cohen delta –1.45). Work package 2 – earlier risk models for posterior capsule rupture and visual acuity loss were broadly affirmed (C-statistic for posterior capsule rupture 0.64; visual acuity loss 0.71). Work package 3 – the Cat-PROM5-based self-reported outcome regression models were derived based on 1181 participants with complete data (R 2 ≈ 30% for each). Of the four preference-based health economic indices assessed, two demonstrated reasonable performance. Cat-PROM5 was successfully calibrated to health economic indices; adjusted limited dependent variable mixture models offered good to excellent fit (root-mean-square error 0.10–0.16). The personalised quantitative risk information was generally perceived as beneficial. A cataract decision aid and cataract decision quality measure were successfully developed based on the views of patients and health-care professionals. Work package 4 – data completeness was good for the feasibility study primary and secondary variables both before and after intervention/surgery (data completeness range 100–88%). Considering ability to recruit, the sample size required, instrumentation and availability of necessary health economic data, a fully powered randomised controlled trial (patients, n = 800, effect size 0.2 standard deviations, power 80%; p = 0.05) of the cataract decision aid would be feasible following psychometric refinement of the primary outcome (the cataract decision quality measure). The cataract decision aid was generally well-received by patients and health-care professionals, with cautions raised regarding perceived time and workload barriers. Discordant outcomes mostly related to patient dissatisfaction, with no clinical problem found. Limitations: The National Ophthalmology Database data are expected to include some errors (mitigated by large multicentre data aggregations). The feasibility randomised controlled trial primary outcome (the cataract decision quality measure) displayed psychometric imperfections requiring refinement. The clinical occurrence of discordant outcomes is uncommon and the study team experienced difficulty identifying patients in this situation. Future work: Future work could include regular review of the risk models for adverse outcomes to ensure currency, and the technical precision of complex-numbers analysis of refractive outcome to invite opportunities to improve post-operative spectacle-free vision. In addition, a fully powered randomised controlled trial of the cataract decision aid would be feasible, following psychometric refinement of the primary outcome (the cataract decision quality measure); this would clarify its potential role in routine service delivery. Conclusions: In this research programme, evidence-based clinical tools have been successfully developed to improve pre-operative decision-making in cataract surgery. These include a psychometrically robust, patient-reported outcome measure (Cat-PROM5); prediction models for patient self-reported outcomes using Cat-PROM5; prediction models for clinically adverse surgical events and adverse visual acuity outcomes; and a cataract decision aid with relevant general information and personalised risk/benefit predictions. In addition, the successful mapping of Cat-PROM5 to existing health economic indices was achieved and the performances of indices were assessed in patients undergoing cataract surgery. A future full-powered randomised controlled trial of the cataract decision aid would be feasible (patients, n = 800, effect size 0.2 standard deviations, power 80%; p = 0.05). Trial registration: This trial is registered as ISRCTN11309852. Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme and will be published in full in Programme Grants for Applied Research; Vol. 10, No. 9. See the NIHR Journals Library website for further project information.
- 26 August 2022
- Published by BMJ in Journal of Epidemiology and Community Health
- Vol. 76 (Suppl 1) , A41.1-A41
OP84 The contribution of thematic analysis of free-text survey data to the quantitative analysis of two clinician surveys of surgical interventions for severe pressure ulcers (PU)
Background Open-ended questions are a common addition to surveys of healthcare practice, yet the free-text responses generated are rarely integrated in substantive findings. There is currently little guidance about how they can be used to enhance survey analysis. In this study we report the qualitative analysis of free-text comments alongside the quantitative analysis of two surveys designed to elicit information from clinicians about reconstructive surgery for pressure ulcers (PU), in terms of referral, treatment, indications and barriers for surgery. The aim was to identify issues not captured by the closed-ended questions, add contextual information to the survey responses and combine quantitative and qualitative results to identify the most important issues influencing referral for surgery. Methods The surveys were completed between June and September 2020 by 137 nurses and 43 surgeons and included 21 and 29 closed-ended questions, respectively, of which 16 (76%) and 23 (79%) had a free-text comment option. We conducted an inductive thematic analysis of the free-text responses using NVivo (QSR International). Results A total of 99 nurses (72%) and 24 surgeons (56%) provided at least one free-text comment, generating a total of 373 and 77 comments, respectively. Themes captured by the free-text responses were grouped into two overarching themes: barriers and contraindications for referral. Barriers were defined as any factor involving the healthcare system/care pathways, while contraindications were defined as any patient-related factor that negatively influences referral. Preliminary analyses identified several barriers that were not captured in the closed-ended questions: i) difficulty in referring patients to appropriate services (nurses and surgeons); ii) surgeon reluctance to operate on/take responsibility for patients outside their direct care (nurses); iii) the current lack of evidence about the effectiveness of reconstructive surgery (nurses and surgeons). The main contraindications, already captured by the closed-ended questions, were patient comorbidities and adherence to post-surgery protocols (nurses and surgeons). Ongoing analysis will attempt to identify sub-themes and rank their relative importance for referral. Conclusion Preliminary analyses revealed that clinicians used free-text comments to highlight barriers to patients receiving reconstructive surgery that were not addressed in the closed-ended questions and reinforce the most important contraindications for surgery. We will argue that embedding and analysing free-text responses in surveys provide further insight into aspects of the topic under investigation not captured by closed-ended questions to highlight directions for future research.
- 26 August 2022
- Published by BMJ in Journal of Epidemiology and Community Health
- Vol. 76 (Suppl 1) , A41.1-A41
OP84 The contribution of thematic analysis of free-text survey data to the quantitative analysis of two clinician surveys of surgical interventions for severe pressure ulcers (PU)
Background Open-ended questions are a common addition to surveys of healthcare practice, yet the free-text responses generated are rarely integrated in substantive findings. There is currently little guidance about how they can be used to enhance survey analysis. In this study we report the qualitative analysis of free-text comments alongside the quantitative analysis of two surveys designed to elicit information from clinicians about reconstructive surgery for pressure ulcers (PU), in terms of referral, treatment, indications and barriers for surgery. The aim was to identify issues not captured by the closed-ended questions, add contextual information to the survey responses and combine quantitative and qualitative results to identify the most important issues influencing referral for surgery. Methods The surveys were completed between June and September 2020 by 137 nurses and 43 surgeons and included 21 and 29 closed-ended questions, respectively, of which 16 (76%) and 23 (79%) had a free-text comment option. We conducted an inductive thematic analysis of the free-text responses using NVivo (QSR International). Results A total of 99 nurses (72%) and 24 surgeons (56%) provided at least one free-text comment, generating a total of 373 and 77 comments, respectively. Themes captured by the free-text responses were grouped into two overarching themes: barriers and contraindications for referral. Barriers were defined as any factor involving the healthcare system/care pathways, while contraindications were defined as any patient-related factor that negatively influences referral. Preliminary analyses identified several barriers that were not captured in the closed-ended questions: i) difficulty in referring patients to appropriate services (nurses and surgeons); ii) surgeon reluctance to operate on/take responsibility for patients outside their direct care (nurses); iii) the current lack of evidence about the effectiveness of reconstructive surgery (nurses and surgeons). The main contraindications, already captured by the closed-ended questions, were patient comorbidities and adherence to post-surgery protocols (nurses and surgeons). Ongoing analysis will attempt to identify sub-themes and rank their relative importance for referral. Conclusion Preliminary analyses revealed that clinicians used free-text comments to highlight barriers to patients receiving reconstructive surgery that were not addressed in the closed-ended questions and reinforce the most important contraindications for surgery. We will argue that embedding and analysing free-text responses in surveys provide further insight into aspects of the topic under investigation not captured by closed-ended questions to highlight directions for future research.
- Open Access
Evaluation of standard and enhanced quality improvement methods to increase the uptake of magnesium sulfate in preterm deliveries for the prevention of neurodisability (PReCePT Study): a cluster randomized controlled trial
Objective: To compare the impact of the National PReCePT Programme (NPP) versus an enhanced Quality Improvement (QI) support programme in improving magnesium sulfate (MgSO 4 ) uptake in English maternity units. Design: Unblinded cluster randomised controlled trial. Setting: England, Academic Health Sciences Network (AHSN), 2018. Participants: Maternity units with ≥10 preterm deliveries annually and MgSO 4 uptake ≤70%. 40 maternity units (27 NPP, 13 enhanced support) were included (randomisation stratified by MgSO 4 uptake). Interventions: NHS England commissioned the NPP to increase MgSO 4 uptake in very preterm deliveries to reduce risk of cerebral palsy. NPP maternity units received PReCePT QI materials, regional support, and midwife backfill funding. Enhanced support units received this plus extra backfill funding and unit-level QI coaching. Outcome measures: MgSO 4 uptake post-implementation was compared between groups using routine data and multivariable linear regression. Net monetary benefit was estimated, based on implementation costs, lifetime quality-adjusted life-years and societal costs. The implementation process was assessed through qualitative process evaluation. Results: MgSO 4 uptake increased in all units, with no evidence of difference between groups (0.84 percentage points lower uptake in the enhanced group, 95% Confidence Interval -5.03 to 3.35 percentage points). The probability of enhanced support being cost-effective was 4 uptake in all maternity units. Enhanced support did not further improve uptake but may improve teamwork, and more accurately represented the time needed for implementation. Targeted enhanced support, sustainability of improvements and the possible indirect benefits of stronger teamwork associated with enhanced support should be explored further. Trial registration: ISRCTN 40938673 ( https://www.isrctn.com/ISRCTN40938673 ) WHAT IS ALREADY KNOWN ON THIS TOPIC: Despite long-standing evidence that Magnesium Sulfate (MgSO 4 ) confers fetal neuroprotection and reduces risk of cerebral palsy in very preterm babies, by 2017 only two-thirds of eligible women in England were receiving it, with wide regional variation. The pilot PReCePT (Prevention of Cerebral Palsy in preterm labour) Quality Improvement (QI) study appeared to effectively accelerate uptake of MgSO 4, and a version of this support model was rolled-out nationwide in 2018. WHAT THIS STUDY ADDS: PReCePT improved MgSO 4 uptake in all maternity units, and the full (‘enhanced’) support model did not appear to improve uptake beyond the achievements of the standard support model used in the National PReCePT Programme. However, enhanced support may be associated with improved perinatal team working, and the funding more accurately represented the staff time needed for implementation. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY: PReCePT may serve as a blueprint for other improvement programs to accelerate uptake of evidence-based interventions, and future studies should consider the potential for indirect but far-reaching benefits to staff and patients.
Open AccessEvaluation of standard and enhanced quality improvement methods to increase the uptake of magnesium sulfate in preterm deliveries for the prevention of neurodisability (PReCePT Study): a cluster randomized controlled trial
Objective: To compare the impact of the National PReCePT Programme (NPP) versus an enhanced Quality Improvement (QI) support programme in improving magnesium sulfate (MgSO 4 ) uptake in English maternity units. Design: Unblinded cluster randomised controlled trial. Setting: England, Academic Health Sciences Network (AHSN), 2018. Participants: Maternity units with ≥10 preterm deliveries annually and MgSO 4 uptake ≤70%. 40 maternity units (27 NPP, 13 enhanced support) were included (randomisation stratified by MgSO 4 uptake). Interventions: NHS England commissioned the NPP to increase MgSO 4 uptake in very preterm deliveries to reduce risk of cerebral palsy. NPP maternity units received PReCePT QI materials, regional support, and midwife backfill funding. Enhanced support units received this plus extra backfill funding and unit-level QI coaching. Outcome measures: MgSO 4 uptake post-implementation was compared between groups using routine data and multivariable linear regression. Net monetary benefit was estimated, based on implementation costs, lifetime quality-adjusted life-years and societal costs. The implementation process was assessed through qualitative process evaluation. Results: MgSO 4 uptake increased in all units, with no evidence of difference between groups (0.84 percentage points lower uptake in the enhanced group, 95% Confidence Interval -5.03 to 3.35 percentage points). The probability of enhanced support being cost-effective was 4 uptake in all maternity units. Enhanced support did not further improve uptake but may improve teamwork, and more accurately represented the time needed for implementation. Targeted enhanced support, sustainability of improvements and the possible indirect benefits of stronger teamwork associated with enhanced support should be explored further. Trial registration: ISRCTN 40938673 ( https://www.isrctn.com/ISRCTN40938673 ) WHAT IS ALREADY KNOWN ON THIS TOPIC: Despite long-standing evidence that Magnesium Sulfate (MgSO 4 ) confers fetal neuroprotection and reduces risk of cerebral palsy in very preterm babies, by 2017 only two-thirds of eligible women in England were receiving it, with wide regional variation. The pilot PReCePT (Prevention of Cerebral Palsy in preterm labour) Quality Improvement (QI) study appeared to effectively accelerate uptake of MgSO 4, and a version of this support model was rolled-out nationwide in 2018. WHAT THIS STUDY ADDS: PReCePT improved MgSO 4 uptake in all maternity units, and the full (‘enhanced’) support model did not appear to improve uptake beyond the achievements of the standard support model used in the National PReCePT Programme. However, enhanced support may be associated with improved perinatal team working, and the funding more accurately represented the staff time needed for implementation. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY: PReCePT may serve as a blueprint for other improvement programs to accelerate uptake of evidence-based interventions, and future studies should consider the potential for indirect but far-reaching benefits to staff and patients.
- 26 March 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 148, 115-123
Confounders and co-interventions identified in non-randomized studies of interventions
- 26 March 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 148, 115-123
Confounders and co-interventions identified in non-randomized studies of interventions
- Open Access
A Qualitative Study of Female Migrant Domestic Workers’ Experiences of and Responses to Work-Based Sexual Violence in Cyprus
Domestic workers face increased risk for sexual harassment and assault in the workplace but are often reluctant to disclose abuse or seek retribution. We report on a study looking at migrant domestic workers’ responses to sexual violence, reasons behind their responses, and factors enhancing or diminishing vulnerability to abuse. We carried out qualitative, in-depth, individual and group interviews with 15 female domestic workers from the Philippines and Sri Lanka working in the Republic of Cyprus. Descriptive thematic analysis was used to analyse data using QSR NVivo 10.0. Sexual violence against migrant domestic workers was reported to be rampant, particularly among women living with their employer. Perpetrators took advantage of women’s precarious legal, social, and economic circumstances to coerce women into a sexual relationship. All participants reported taking action to stop attacks despite the significant barriers they faced: racism and discrimination, social isolation, and hostile legal, labour, and immigration systems. Fear of losing their job, being deported, and facing racism and discrimination from the police were the biggest barriers to seeking retribution. Access to informational, e.g., legal, practical, and emotional support, facilitated positive outcomes following abuse, such as finding a new employer. Systemic racism, hostile labour and immigration systems, and lack of support increase risk of sexual violence and place barriers against accessing safe working spaces, protection, and justice. Women need to be informed of the risks involved in domestic work and empowered to identify abuse and access help and support when needed.
Open AccessA Qualitative Study of Female Migrant Domestic Workers’ Experiences of and Responses to Work-Based Sexual Violence in Cyprus
Domestic workers face increased risk for sexual harassment and assault in the workplace but are often reluctant to disclose abuse or seek retribution. We report on a study looking at migrant domestic workers’ responses to sexual violence, reasons behind their responses, and factors enhancing or diminishing vulnerability to abuse. We carried out qualitative, in-depth, individual and group interviews with 15 female domestic workers from the Philippines and Sri Lanka working in the Republic of Cyprus. Descriptive thematic analysis was used to analyse data using QSR NVivo 10.0. Sexual violence against migrant domestic workers was reported to be rampant, particularly among women living with their employer. Perpetrators took advantage of women’s precarious legal, social, and economic circumstances to coerce women into a sexual relationship. All participants reported taking action to stop attacks despite the significant barriers they faced: racism and discrimination, social isolation, and hostile legal, labour, and immigration systems. Fear of losing their job, being deported, and facing racism and discrimination from the police were the biggest barriers to seeking retribution. Access to informational, e.g., legal, practical, and emotional support, facilitated positive outcomes following abuse, such as finding a new employer. Systemic racism, hostile labour and immigration systems, and lack of support increase risk of sexual violence and place barriers against accessing safe working spaces, protection, and justice. Women need to be informed of the risks involved in domestic work and empowered to identify abuse and access help and support when needed.